Tag: MDMA

BLS Pharmaceuticals (ASX: BLS) has reported a record FY26, with revenue climbing 161% to $74.2 million and Adjusted EBITDA rising ...

Psychedelic medicine has spent the past decade developing clinical evidence almost exclusively in adults. Adolescents have largely remained outside the ...

For decades, psychedelic medicine sat on the margins of psychiatry, constrained by international drug controls, political controversy and the legacy ...

A new executive order could position the US territory as a research destination for emerging psychedelic therapies as clinicians, researchers ...

Emyria is building a second business behind its growing mental health operation: a drug discovery and development programme focused on ...

Australia's psychedelic medicine industry has crossed the regulatory threshold. Since 1 July 2023, specifically authorised psychiatrists have been able to ...

As psychedelic-assisted therapy moves from research into clinical practice in Australia, the organisations building the infrastructure around the sector are ...

BLS Pharmaceuticals (ASX: BLS) has signed a referral agreement with US-based Cayman Chemical Company, expanding its international commercial network for ...

Medicinal cannabis and psychedelic medicine are often discussed as part of the same healthcare revolution. Both involve substances that spent ...

As psychedelic medicine edges closer to mainstream clinical practice, Europe is approaching a pivotal moment that could shape the sector ...